Phaseline

Companies › Grace Science

Grace Science: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GS-100
Gene replacement therapy for NGLY1 deficiency delivered via intracerebroventricular admini
NGLY1Phase 3NGLY1 DeficiencyMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06199531GS-100Phase 3NGLY1 DeficiencyMetabolic and endocrineMar 2027

From the company's SEC filings

Cash of $14m on 2026-06-30; operating cash outflow about $13m a year; runway about 13 months at that burn, to Jul 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Complete response letters from FDA

Targets

NGLY1 (1)

Companies with the same targets

–

Companies built like this

Yong Zhao, MD, PhD Spur Therapeutics iECURE BioLab Holdings AB Biotics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.